🟢 Neurosense Therapeutics is trading 11.6% up today on continued optimism for its ALS drug PrimeC

Neurosense Therapeutics is trading 11.6% up today at $0.58 as momentum continues to build around the company's lead ALS candidate, PrimeC.

• The move extends gains following the July 22 announcement of plans to file a New Drug Submission with Health Canada for PrimeC.
• Investor sentiment is further bolstered by a broadly positive biotech sector and firm performance across the overall equity markets.